philippe monnot

About philippe monnot

Philippe Monnot is a recognized figure in French entrepreneurial investment and the governance of innovative companies. At CROSSJECT, he serves as Chairman of the Supervisory Board, a role that places him at the center of the company’s long-term governance framework. CROSSJECT states that he is also one of the company’s historic backers through Gemmes Venture, the investment vehicle he co-founded in 1999 and co-leads. Gemmes Venture was CROSSJECT’s first shareholder, underscoring Monnot’s early and lasting involvement in the company’s development. A graduate of emlyon business school, Monnot has built a profile as an investor and ecosystem builder with a strong focus on healthcare, alongside exposure to digital services, fintech and cleantech. CROSSJECT’s governance materials indicate that Gemmes Venture was among the founding shareholders of several healthcare-related companies, including ASTEN SANTÉ, H2AD TELEHEALTH and VIVALIB. This background points to substantial expertise in spotting high-potential ventures, structuring equity investments, and supporting technology and healthcare businesses across different stages of growth. Within CROSSJECT’s ecosystem, Monnot represents stable shareholding and a governance mindset focused on industrial and regulatory value creation. CROSSJECT develops ZENEO®, a needle-free auto-injection platform, and the Supervisory Board plays a key role in supporting strategy, financing, clinical milestones and industrial execution. Monnot’s position therefore reflects the combination of investor perspective, commitment to entrepreneurship and long-term involvement in high-technology healthcare businesses. His career illustrates an ability to align capital, governance discipline and strategic support in order to help scale innovative companies.